Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

1656 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-22

Study Completion Date

2028-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a multi-centre, Open-label, Randomized Controlled, 1:1 trial comparing Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus standard DAPT regimen in STEMI patients in terms of safety and efficacy endpoints.

In the subgroup of STEMI patients with MVD, a sub-randomization will allow a comparison between a complete revascularization OCT-guided versus complete revascularization angiography-guided stent in terms of efficacy and safety endpoints.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction

NCT00976092

Myocardial Infarction

UNKNOWN PHASE4

Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy

NCT04766437

Non ST Segment Elevation Acute Coronary Syndrome

COMPLETED PHASE2

Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients

NCT02639143

Inflammation Thrombosis

COMPLETED PHASE4

Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse

NCT01336348

ST Segment Elevation Myocardial Infarction

COMPLETED PHASE3

Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI

NCT00546260

Myocardial Infarction

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Consecutive patients with STEMI planned for pPCI will be screened for eligibility criteria and treated as per standard of care with ASA and Prasugrel 60 mg loading dose. The culprit lesion will be treated during the index procedure. Non culprit lesions in patients with MVD will be treated during staged procedure(s), in any case last instalment of staged procedure(s) should be scheduled within 15 days after index procedure. Complete revascularization of non culprit lesions will be allocated to either OCT- or angio-guided strategy (OCT randomization). At 30-45 days follow-up after index procedure, if inclusion criteria are met, patients will be randomized to prasugrel monotherapy or standard DAPT regimen (DAPT randomization).

The follow-up duration is 35 months after DAPT randomization, i.e. clinical outcomes will be analysed at 11 and 35 months after DAPT randomization.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ST Elevated Myocardial Infarction Dual Antiplatelet Therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prasugrel-based short DAPT

Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy for 11 months.

Group Type EXPERIMENTAL

Prasugrel based short DAPT

Intervention Type DRUG

Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus

Prasugrel based standard DAPT

Prasugrel-based DAPT for 1 year

Group Type ACTIVE_COMPARATOR

Prasugrel based standard DAPT

Intervention Type DRUG

Prasugrel based DAPT for 1 year

OCT guided non-culprit lesion

Complete revascularization of non culprit lesions guided by OCT

Group Type EXPERIMENTAL

OCT guided revascularization

Intervention Type DEVICE

OCT guided revascularization of the non-culprit lesions

Angio guided non-culprit lesion

Complete revascularization of non culprit lesions guided by Angio

Group Type ACTIVE_COMPARATOR

Angio guided revascularization

Intervention Type DEVICE

Angio guided revascularization of the non-culprit lesions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prasugrel based short DAPT

Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus

Intervention Type DRUG

Prasugrel based standard DAPT

Prasugrel based DAPT for 1 year

Intervention Type DRUG

OCT guided revascularization

OCT guided revascularization of the non-culprit lesions

Intervention Type DEVICE

Angio guided revascularization

Angio guided revascularization of the non-culprit lesions

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Eligibility at index procedure

All STEMI patients who are planned to be treated with PCI:

ST segment elevation myocardial infarction

Chest discomfort suggestive of cardiac ischemia ≥20 min at rest with 1 of the following ECG features:

* ST segment elevation ≥2 contiguous ECG leads
* new or presumably new left bundle branch block

In patients with multivessel disease, treatment only of the culprit lesion / target vessel during primary PCI is recommended.

Eligibility at 30-45 days

* All patients who have provided informed consent
* Compliance to DAPT with no regimen modifications (Non-adherence Academic Research Consortium 0)
* No occurrence of significant event (such as MI, unplanned revascularisation, stent thrombosis, stroke, major vascular complication/bleeding BARC Types 3 or greater).
* Successful revascularization: - Successful delivery and deployment of the Study device(s), with final residual stenosis of \<30% (visually) for all target lesions.
* Complete revascularization performed when more than 1 significant lesion, during the index procedure or in staged procedure(s) occurring within 15 days from the index procedure. Physiologic assessment highly recommended for lesions with stenosis between 50% and 90%.

Exclusion Criteria

* Patients on oral anticoagulation
* Contraindication to P2Y12 inhibitors and/or to Cardioaspirin or to any of the excipients (hypersensitivity, history of any stroke or transient ischemic attack within the last 12 months, active bleeding or haemorrhagic diathesis, fibrin-specific fibrinolytic therapy less than 24 h before randomization, severe hepatic dysfunction (Child-Pugh C), history of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory medicines, history of gastrointestinal perforation or acute gastrointestinal ulcers, severe cardiac failure (NYHA grade III or IV), combination with methotrexate at doses of 15 mg/week or more).
* Patients who have received P2Y12 inhibitors other than Prasugrel in the ambulance (Ticagrelor or Clopidogrel loading dose) or are already on P2Y12 inhibitors, may be enrolled in the protocol, provided that the Prasugrel loading dose is administered at admission, according to current guidelines recommendations (see section 5.2.2).
* Concomitant oral or i.v. therapy with strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice \>1L/day), CYP3A substrates with narrow therapeutic indices (e.g., cyclosporine, quinidine), or strong CYP3A inducers (e.g., rifampin), - rifampicin, phenytoin, carbamazepine, dexamethason, phenobarbital
* Platelet count \<100.000/μL at the time of screening
* Anemia (hemoglobin \<10 g/dL) at the time of screening
* Comorbidities associated with life expectancy \<1 year
* Pregnancy, giving birth within the last 90 days, or lactation (see appendix III for women of childbearing potential)
* PCI indication for stent thrombosis or previous history of definite stent thrombosis
* Non-deferrable major surgery on DAPT after PCI
* Cardiogenic shock
* Out of hospital cardiac arrest (OHCA) unless survivors of ventricular arrythmia with prompt return of spontaneous circulation (ROSC)
* Patients with severe renal impairment: creatinine clearance ≤30 ml/min/1.73 m2 (as calculated by MDRD formula for estimated GFR).
* Patients participating in another interventional (device of drug trial) within the previous 12 months or patients to whom an investigational drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer.
* No informed consent

Eligible Sex

ALL

Accepts Healthy Volunteers

No